Profound Medical to Host Investor Call on March 13 to Discuss First Clinical Outcomes from Pivotal CAPTAIN Trial
PROF sits 33% above its 52-week low of $3.76.
Summary
Profound Medical announced an investor conference call on March 13, 2026, to discuss the first clinical outcomes from its pivotal CAPTAIN trial, which compares the TULSA Procedure to robotic radical prostatectomy.
Key Events · Product Development and Regulatory · PROF
-
CAPTAIN Trial Outcomes Presentation
The first clinical outcomes from the Level 1 post-market CAPTAIN trial, comparing the TULSA Procedure™ with robotic radical prostatectomy, are scheduled for presentation at the 41st Annual European Association of Urology (EAU 2026) Congress on March 13, 2026.
-
Investor Conference Call Scheduled
Profound Medical will host an investor webinar on March 13, 2026, at 11:30 a.m. ET, where Dr. Laurence Klotz will review the CAPTAIN data and its clinical relevance, and management will discuss commercial implications and next steps for treatment guideline inclusion.
-
Participation in ROTH Conference
Management will also participate in one-on-one investor meetings at the 38th Annual Roth Conference from March 22-24, 2026.
Analysis · PROF · Industrial Applications And Services
This 8-K announces a critical upcoming event for Profound Medical: the presentation and discussion of the first clinical outcomes from its Level 1 post-market CAPTAIN trial. This trial directly compares the TULSA Procedure™ to robotic radical prostatectomy for prostate cancer, making its results highly influential for market adoption and potential inclusion in treatment guidelines. Positive outcomes could significantly enhance the company's competitive position and drive future sales of its TULSA-PRO system. Investors will be closely watching the March 13 webinar for detailed data and management's commercial implications.
At the time of this filing, PROF was trading at $5.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $181.3M. The 52-week trading range was $3.76 to $8.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.